Ana Graf
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer's Prevention Initiative Generation Study 1.
Journal: The lancet. Healthy longevity
Published: April 29, 2025
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: September 06, 2024
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 23, 2024
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 22, 2024
Revised criteria for the diagnosis and staging of Alzheimer's disease.
Journal: Nature medicine
Published: June 28, 2024
Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: April 26, 2024
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: February 07, 2024
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: August 16, 2023
Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.
Journal: The journal of prevention of Alzheimer's disease
Published: June 25, 2023
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: April 27, 2023
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease.
Journal: Alzheimer's research & therapy
Published: November 01, 2022
Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpoints.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: August 10, 2022
Last Updated: 09/26/2026